Atherosclerosis is one of the main causes of vascular disease all over the world. Ischemic heart disease, ischemic stroke, and peripheral artery disease are some of the most prevalent clinical manifestations of this condition. Acute coronary syndrome (ACS), transient ischemic attack (TIA) or small stroke, and peripheral artery disease are all treated and prevented with antiplatelet medication in the majority of cases. Clopidogrel was the first of the P2Y12 inhibitors to be developed, and these drugs are now widely used in the primary and secondary prevention of cardiovascular disease. This article summaries the current research on the effectiveness of antiplatelet therapy for atherosclerosis patients, with particular emphasis on clopidogrel. Clopidogrel's potential side effects and risks, as well as the drug's contraindications and toxicity characteristics, are discussed.